A5101636838- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Head and Neck Surgical Oncology
- Acute Myeloid Leukemia Research
- Salivary Gland Tumors Diagnosis and Treatment
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Chronic Myeloid Leukemia Treatments
- Ear and Head Tumors
- Cancer Treatment and Pharmacology
- Oral health in cancer treatment
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
- HER2/EGFR in Cancer Research
- Tracheal and airway disorders
- Acute Lymphoblastic Leukemia research
University of Washington
2015-2025
Fred Hutch Cancer Center
2017-2023
Henry Ford Hospital
2023
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2014-2020
Cancer Research Center
2017-2020
Seattle Cancer Care Alliance
2014-2020
University of Washington Medical Center
2016-2017
Cleveland Clinic
2004-2014
Oregon Health & Science University
2012-2013
Duke University Hospital
2007-2009
Treatment is complex for patients with head and neck (H&N) cancers specific site of disease, stage, pathologic findings guiding treatment decision-making. planning H&N involves a multidisciplinary team experts. This article describes supportive care recommendations in the NCCN Guidelines Head Neck Cancers, as well rationale supporting new section on imaging cancers. also updates to very advanced salivary gland tumors, specifically systemic therapy recommendations.
<section class="abstract"><p id="P1">The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations cancers of the lip, oral cavity, pharynx, larynx, ethmoid maxillary sinuses, salivary glands. Recommendations are also provided occult primary H&N, separate algorithms have been developed by panel very advanced H&N cancers. These Insights summarize panel's discussion most recent regarding evaluation nasopharyngeal carcinoma. </section>
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations cancers of the lip, oral cavity, pharynx, larynx, ethmoid maxillary sinuses, salivary glands. Recommendations are also provided occult primary head neck (H&N), separate algorithms have been developed by panel very advanced H&N cancers. These Insights summarize panel's discussion most recent regarding increase human papillomavirus–associated oropharyngeal cancer...
The aim of the current work is to provide evidence-based recommendations practicing physicians and others on management neck in patients with squamous cell carcinoma oral cavity oropharynx.ASCO convened an Expert Panel medical oncology, surgery, radiation advocacy experts conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, prospective retrospective comparative observational studies published from 1990 through 2018. Outcomes interest...
PURPOSE To provide evidence-based recommendations to practicing physicians and other health care providers on the diagnosis management of squamous cell carcinoma unknown primary in head neck (SCCUP). METHODS The American Society Clinical Oncology convened an Expert Panel medical oncology, surgery, radiation radiology, pathology, advocacy experts conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, prospective retrospective comparative...
Abstract RET fusions are oncogenic drivers of various tumors, including non–small cell lung cancers (NSCLC). The safety and antitumor activity the multikinase inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended II dose 275 mg fed daily was identified. most common treatment-related adverse events fatigue (25%), diarrhea (24%), hypophosphatemia (18%), maculopapular rash nonmaculopapular (17%). In Ib cohort inhibitor–naïve patients with fusion–positive NSCLCs, objective...
Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated controversial. We aimed to assess whether radiotherapy concurrent adjuvant durvalumab would improve outcomes compared cetuximab.
ABSTRACT Background Head and neck mucosal melanoma (HNMM) is rare carries a poor prognosis with high rates of disease progression. There little data regarding the use adjuvant proton radiation therapy in management sinonasal HNMM. Aims We performed retrospective review patients nonmetastatic HNMM treated from 2012 to 2022 at single academic institution. Kaplan–Meier estimates were used for survival analyses. Methods Results Eight surgery radiation, six received systemic therapy. Median...
Abstract Background The reported decreasing benefit with increasing age from concurrent chemoradiotherapy in head and neck cancer patients prompted this retrospective review. Methods Two courses of cisplatin‐based were given to fit ≥70 years locoregionally advanced cancers. Clinical characteristics, treatment, outcomes compared those for an identically treated cohort <70 years. Results There 44 137 treatment toxicities similar except that the elderly less likely receive both chemotherapy...
Currently, no systemic treatments are approved for patients with recurrent and/or metastatic (R/M) adenoid cystic carcinoma (ACC). PRT543, a protein arginine methyltransferase 5 inhibitor that downregulates NOTCH1 and MYB signalling in tumours, is potential candidate R/M ACC treatment. We report the safety, tolerability preliminary efficacy of PRT543 dose-expansion cohort ACC.
Abstract Background Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, toxicity in recurrent/metastatic head neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). Methods In this single‐institution retrospective cohort study, a dataset of patients R/M HNSCC ICIs 08/2012–03/2021 was established, including demographic clinicopathologic characteristics. Pretreatment PBBMs were collected evaluated for...
6046 Background: Notch signaling plays a key role in ACC tumorigenesis. mut are found ̃20% of tumors, which aggressive with poor prognosis. Approved or standard therapies for relapsed/metastatic lacking, regardless status. Investigational drug AL101, γ-secretase inhibitor, blocks and inhibits tumor growth patient-derived xenografts. AL101 has clinical activity at 4 mg once weekly (QW) disease control rate (DCR) 68% (15% partial response, (PR)) appears to be well tolerated. An additional...
Abstract Background Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head neck squamous cell carcinoma (HN) salivary gland cancer (SGC) treated with pembrolizumab vorinostat on a phase II trial (NCT02538510). Experimental Design Twenty‐five HN 25 SGCs vorinostat. Baseline was available 21 20 evaluated for associations grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS),...
To determine whether vocal cord fixation precludes nonsurgical management of T3/T4 laryngeal carcinoma.A retrospective chart review.Between 1989 and 2005 patient records with squamous cell carcinoma the larynx at presentation were reviewed. All treated a concomitant cisplatin-based chemoradiotherapy protocol part institutional head neck cancer registry. Only patients adequate pre- post-treatment fiberoptic evaluations included. Charts reviewed for demographics tumor characteristics; return...
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 21% of gastric and 33% gastroesophageal junction (GEJ) adenocarcinomas. Trastuzumab has been approved for metastatic HER2‐positive gastric/GEJ cancer combination with chemotherapy. This retrospective analysis was undertaken to better define the clinicopathologic features, treatment outcomes, prognosis patients adenocarcinoma esophagus/GEJ. Pathologic specimens from 156 esophagus/GEJ treated on clinical trials chemoradiation...
This phase II study tested the addition of oral epidermal growth factor receptor gefitinib to multiagent concurrent chemoradiotherapy regimen in head and neck squamous cell cancer (HNSCC).Patients with stage III-IV HNSCC received hyperfractionated radiation (72-74.4 Gy at 120 cGy twice daily), 96-hour infusions cisplatin 20 mg/m(2) /day fluorouracil 1000 given during weeks 1 4. Daily 250 mg was started on day continued for 2 years. Results were retrospectively compared our previous using...
Chemoradiotherapy results in excellent outcomes locally advanced head and neck squamous cell carcinoma (HNSCC). This trial compared 2 chemoradiotherapy regimens.Patients with HNSCC were treated radiation (70-74.4 Gy), randomized to arm A: cisplatin 100 mg/m(2) on radiotherapy (RT) days 1, 22, 43, or B: (20 /day) 5-fluorouracil (5-FU; 1000 continuous 96-hour infusions RT weeks 1 4. The primary endpoint was relapse-free survival (RFS).Between February 2008 October 2011, 69 patients enrolled...
6013 Background: Immuno-STATs are modular T cell engagers engineered to selectively activate tumor-antigen specific CD8+ cells via targeted delivery of cytokines. CUE-101, the first Immuno-STAT in clinical trials, is composed a human leukocyte antigen (HLA) complex, HLA-A*0201, peptide epitope derived from HPV16 E7 protein, and 4 molecules attenuated interleukin-2 (IL-2) designed bind, expand, HPV16-specific for treatment HPV16+ cancers. Methods: CUE-101-01 an ongoing first-in-human study...